Take­da says TYK2 drug it pur­chased for $4B has passed an­oth­er mid-stage test

Take­da an­nounced Mon­day morn­ing that the TYK2 in­hibitor it bought from Nim­bus Ther­a­peu­tics for $4 bil­lion has suc­ceed­ed in a Phase IIb tri­al in pso­ri­at­ic arthri­tis.

While Take­da didn’t share any specifics, it said that in the Phase IIb study, a greater pro­por­tion of pa­tients treat­ed with its once-a-day pill, TAK-279, saw at least 20% im­prove­ment on a mea­sure of a core group of symp­toms of the dis­ease com­pared to place­bo at three months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER